Investors are bidding up these biotechs in response to the health threat.
Aurora's stock is simply too risky to own at this critical juncture.
Aphria's stock may be one of the few worthwhile buys in the volatile cannabis industry.
Inovio was awarded a $9 million grant to develop a vaccine against the emerging coronavirus threat.
Dividend investors may want to strongly consider buying AbbVie and Gilead Sciences right now.
The vaccine maker's stock is getting a lift from a pair of catalysts this morning.
BeiGene and Vertex Pharmaceuticals aren't nearly as expensive as you may think.
HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.
Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.
Catalyst appears poised for a strong 2020.
Geron has a long road ahead. Is this speculative biotech stock worth the wait?
The outbreak of a deadly respiratory virus caused Novavax's shares to take flight yesterday. Can the biotech's stock climb even higher, or is it time to take profits?
These stocks could thump the broader markets this year.
Can Dynavax's stock rebound after a dreadful 2019?
The drugmaker's planned metamorphosis failed to impress investors, but that wasn't its only headwind.
Canopy Growth and Cronos Group are in a class of their own among legal pot plays.
Biogen's decision to forgo a major deal weighed on its shares in 2019.
AbbVie's shares had an off year in 2019. Here's why.
Which of these two biotech giants is the better buy in 2020?
The Canadian cannabis grower and distributor had a dreadful 2019 that sent its shares tumbling to levels that could be tempting for bargain hunters.